Biomarker could improve prediction of response to immunotherapy in melanoma
Source: Medical Xpress, May 2024
If melanoma spreads, there are various therapies that can be used. However, there is still insufficient research into who responds to which therapy and whether resistance may develop over time.
In a new study, Dr. Simon Fietz, assistant physician at the Clinic for Dermato-oncology & Phlebology at the Center for Skin Diseases at the University Hospital Bonn (UKB) and PD Dr. Dimo Dietrich, scientist at the Clinic and Polyclinic for Otorhinolaryngology at the UKB, have discovered that a specific liquid biopsy biomarker harbors the potential to identify the effectiveness of a treatment at an early stage.
This could enable a more individualized treatment for patients with melanoma. The results have now been published in Clinical Chemistry.